JUL 07, 2020 2:48 PM PDT

Drug Shows Promise for ALS Treatment

WRITTEN BY: Nouran Amin

Researchers have announced that an experimental drug showed promising results for a rare and inherited form of amyotrophic lateral sclerosis (ALS). The drug, referred to as ‘tofersen’, was evaluated based on safety and efficacy in both phase 1 and phase 2 clinical trials carried at Washington University School of Medicine in St. Louis, Massachusetts General Hospital in Boston. 

Tofersen showed evidence in lowering the culprit protein concentration that leads to the symptoms of ALS. Such promising results, published July 9 in the New England Journal of Medicine, have launched the phase 3 clinical trial with hopes to continue evaluation. 

"ALS is a devastating, incurable illness," said principal investigator Timothy M. Miller, MD, PhD, the David Clayson Professor of Neurology at Washington University and director of the ALS Center at the School of Medicine. "While this investigational drug is aimed at only a small percentage of people with ALS, the same approach -- blocking the production of specific proteins at the root of the illness -- may help people with other forms of the illness. 

Learn more about amyotrophic lateral sclerosis (ALS): 

 

"This trial indicated that tofersen shows evidence of safety that warrants further investigation and that the dose we used lowers clinical markers of disease. There are even some signs that it slowed clinical progression of ALS, although the study was not designed to evaluate effectiveness at treating the disease, so we can't say anything definitive. Overall, the results are just what we hoped for, and a phase 3 trial is currently underway." 

Source: Science Daily 

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
SEP 20, 2020
Drug Discovery & Development
New Drug Combo Prolongs Survival with Advanced Kidney Cancer
SEP 20, 2020
New Drug Combo Prolongs Survival with Advanced Kidney Cancer
Biopharmaceutical company Bristol-Myers Squibb has found that a new drug combination can reduce death rates among those ...
SEP 20, 2020
Drug Discovery & Development
New Drug Shows Promise in Treating Advanced COVID-19
SEP 20, 2020
New Drug Shows Promise in Treating Advanced COVID-19
As the COVID-19 pandemic rages on, the search for drugs to combat the virus is ongoing. Now, scientists have found that ...
OCT 01, 2020
Drug Discovery & Development
HPV Vaccine Protects Against Cervical Cancer, Large Study Finds
OCT 01, 2020
HPV Vaccine Protects Against Cervical Cancer, Large Study Finds
It has been known for some time that the HPV vaccine protects against human papillomavirus infection, genital warts, and ...
NOV 03, 2020
Cardiology
A New Peptide Could Help Repair and Protect the Heart During Ischemia Reperfusion Injury
NOV 03, 2020
A New Peptide Could Help Repair and Protect the Heart During Ischemia Reperfusion Injury
Cardiovascular disease is one of the most common causes of death in the world. Although we have many treatments against ...
NOV 08, 2020
Cell & Molecular Biology
Mouth Spray for Epidermolysis Bullosa in Development
NOV 08, 2020
Mouth Spray for Epidermolysis Bullosa in Development
Epidermolysis Bullosa (EB) is a rare genetic disorder that makes the skin incredibly fragile; it forms blisters and can ...
NOV 22, 2020
Cannabis Sciences
Public Believes CBD is Cure-All Despite Lack of Evidence
NOV 22, 2020
Public Believes CBD is Cure-All Despite Lack of Evidence
Many people think that cannabidiol (CBD), a non-psychoactive compound in cannabis, can reduce symptoms from various cond ...
Loading Comments...